Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Regulatory News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.00 (0.00%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £91.78m
FARN Live PriceLast checked at - London Stock Exchange

Intraday Faron Pharmaceuticals Share Chart

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

12 Mar 2026 14:30

Faron Pharmaceuticals Ltd | Company announcement | March 12, 2026 at 16:30:00 EET

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuerX
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rightsx
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii: Dividend payments in kind.x
3. Details of person subject to the notification obligation iv
NameTimo Syrjälä
City and country of registered office (if applicable)Monaco
4. Full name of shareholder(s) (if different from 3.) v
NameAcme Investments SPF Sarl
City and country of registered office (if applicable)Luxembourg
5. Date on which the threshold was crossed or reached vi:10.03.2026
6. Date on which issuer notified (DD/MM/YYYY):11.03.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached13.9013.9016.093.129
Position of previous notification (ifapplicable)14.9614.9617.120.400
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type ofsharesISIN code (if possible)Number of voting rights ix% of voting rights
Direct(DTR5.1)Indirect(DTR5.2.1)Direct(DTR5.1)Indirect(DTR5.2.1)
FI40001533095.745.11210.348.0174.96%8.94%
SUBTOTAL 8. A16.093.12913.90%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrumentExpirationdate xExercise/ Conversion Period xiNumber of voting rights that may be acquired if the instrument isexercised/converted.% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrumentExpirationdate xExercise/ Conversion Period xiPhysical or cashSettlement xiiNumber of voting rights% of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark theapplicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xivX
Name xv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Timo Syrjälä (Direct)4.96%4.96%
Acme Investments SPF Sarl (Indirect)8.94 %8.94 %
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
Place of completionMonaco
Date of completion11.3.2026
Date   Source Headline
3rd Jun 202612:00 pmMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Registration of New Shares
3rd Jun 20267:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
1st Jun 20261:00 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
28th May 20262:00 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
28th May 20261:35 pmMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company
28th May 20261:30 pmMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Special Rights attached to the First and Second Tranche of Bonds
18th May 20267:00 amMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
6th May 20266:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Termination of Liquidity Provision Service
5th May 20267:30 amMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
5th May 20266:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Directorate Appointment
4th May 202611:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Results of the Annual General Meeting
30th Apr 20266:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Issuance of warrants
22nd Apr 202611:30 amMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
20th Apr 20267:15 amMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
20th Apr 20267:00 amMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
16th Apr 20263:00 pmMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
14th Apr 202612:15 pmMFNFaron Pharmaceuticals Ltd: Remaining offer shares registered with Finnish Trade Register
14th Apr 20267:45 amMFNFaron Pharmaceuticals Ltd: Registration of New Shares
13th Apr 202611:00 amMFNFaron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
10th Apr 20261:30 pmMFNNOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING
10th Apr 202612:55 pmMFNFaron Pharmaceuticals Ltd: New shares registered with Finnish Trade Register
9th Apr 20265:25 pmMFNFaron publishes final results of its EUR 40.1 million rights issue
8th Apr 20262:15 pmMFNInside Information: Faron publishes preliminary results of its successful rights issue
31st Mar 20266:00 amMFNFaron Pharmaceuticals Ltd: Director Dealing
30th Mar 20267:30 amRNSSuspension - Faron Pharmaceuticals Oy
26th Mar 20267:00 amMFNFaron Pharmaceuticals Ltd: Faron appoints new CTO to strengthen late-stage development activities
25th Mar 20268:00 amMFNFaron Pharmaceuticals Ltd: Director Dealing
24th Mar 20264:30 pmMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
19th Mar 20267:10 amMFNFaron Pharmaceuticals Ltd: Director Dealing
19th Mar 20267:05 amMFNFaron Pharmaceuticals Ltd: Director Dealing
19th Mar 20267:00 amMFNFaron Pharmaceuticals Ltd: Director Dealing
12th Mar 20262:30 pmRNSFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
12th Mar 20262:30 pmMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
11th Mar 20266:20 pmRNSThe Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus
11th Mar 20266:20 pmMFNThe Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus
11th Mar 20268:00 amRNSFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
10th Mar 20267:48 amRNSInside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway
10th Mar 20267:48 amMFNInside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway
9th Mar 20265:45 pmMFNUpdate to Faron's Financial Calendar and date of the Annual General Meeting in 2026
4th Mar 20264:45 pmMFNCorrection: Faron Pharmaceuticals Ltd's Annual Report 2025 published
4th Mar 20267:15 amMFNFaron Pharmaceuticals Ltd's Annual Report 2025 published
4th Mar 20267:00 amMFNFaron's Financial Statements Release 1 January to 31 December 2025
2nd Mar 202610:00 amMFNFaron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting
9th Feb 20265:45 pmMFNFaron Pharmaceuticals Ltd: NOTICE TO THE EXTRAORDINARY GENERAL MEETING
9th Feb 20265:35 pmMFNInside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones
3rd Feb 20264:00 pmMFNFaron Pharmaceuticals Ltd: Registration of New Shares
3rd Feb 20267:00 amMFNFaron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
13th Jan 20264:00 pmMFNFaron Pharmaceuticals Ltd: PDMR Dealing
8th Jan 20265:45 pmMFNFaron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds
17th Dec 20252:30 pmMFNComposition of Faron Pharmaceutical's Shareholders' Nomination Board

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.